- Business Wire•yesterday
ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
ArQule, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 9,630,968. The patent claims composition of matter of ARQ 531. ArQule will be entitled to patent protection through December 2035 in the U.S.
- Business Wire•8 days ago
ArQule, Inc. today announced it will report financial results for the first quarter 2017 before the market opens on Wednesday, May 3, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m.
- Business Wire•16 days ago
ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
ArQule, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration for the Investigational New Drug application to conduct a phase 1 clinical trial with ARQ 531 in patients with B-cell malignancies who are refractory to other therapeutic options.
ARQL : Summary for ArQule, Inc. - Yahoo Finance
ArQule, Inc. (ARQL)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.01 x 200|
|Ask||1.03 x 3500|
|Day's Range||1.00 - 1.03|
|52 Week Range||0.92 - 2.17|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|